Abeona Therapeutics Inc vs Teucrium Soybean Fund — how do they compare? Abeona Therapeutics Inc trades at $7.39 (market cap $421.19M), while Teucrium Soybean Fund trades at $24.82. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Teucrium Soybean Fund nearer its low. Which is the better fit depends on your goals.
| ABEO | SOYB | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.45 | $26.28 |
52-Week Low | $4.17 | $21.46 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
No Aura AI signal available yet.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →